Two-Week Direct-Acting Antiviral Prophylaxis for Kidney Transplantation From Donors With Hepatitis C Viremia to Recipients Without Hepatitis C Viremia: A Small Uncontrolled Trial

Ann Intern Med. 2023 Dec;176(12):1682-1684. doi: 10.7326/M23-2682. Epub 2023 Nov 28.

Authors

Niraj M Desai¹, Sherry G Leung¹, Jennifer D Motter², Dorry L Segev³, Daniel Warren¹, Christine M Durand⁴

Affiliations

¹ Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.
² Department of Surgery, New York University Grossman School of Medicine, New York, New York.
³ Department of Surgery and Department of Population Health, New York University Grossman School of Medicine, New York, New York.
⁴ Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.

PMID: 38011702
DOI: 10.7326/M23-2682

No abstract available

Publication types

Letter

MeSH terms

Antiviral Agents / therapeutic use
Hepacivirus
Hepatitis C* / drug therapy
Hepatitis C* / prevention & control
Hepatitis C, Chronic* / drug therapy
Humans
Kidney Transplantation*
Tissue Donors
Viremia

Substances

Antiviral Agents